[go: up one dir, main page]

PE20010546A1 - USE OF A COMPOSITION OF BENZOHETERO CYCLES AS MEK INHIBITORS TO TREAT CHRONIC PAIN - Google Patents

USE OF A COMPOSITION OF BENZOHETERO CYCLES AS MEK INHIBITORS TO TREAT CHRONIC PAIN

Info

Publication number
PE20010546A1
PE20010546A1 PE2000000704A PE0007042000A PE20010546A1 PE 20010546 A1 PE20010546 A1 PE 20010546A1 PE 2000000704 A PE2000000704 A PE 2000000704A PE 0007042000 A PE0007042000 A PE 0007042000A PE 20010546 A1 PE20010546 A1 PE 20010546A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
phenyl
composition
methyl
Prior art date
Application number
PE2000000704A
Other languages
Spanish (es)
Inventor
Kevin Lee
Haile Tecle
Alexander James Bridges
Stephen Douglas Barrett
Alistair Dixon
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010546A1 publication Critical patent/PE20010546A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

SE REFIERE AL USO DE UNA COMPOSICION QUE COMPRENDE UN INHIBIDOR DE CINASA MEK DE FORMULA I, DONDE: W ES OR1, NR2OR1, NRARB, NR2NRARB, O(CH2)2-4NRARB, NR2(CH2)2-4, R1 ES H, ALQUILO C1-C8, ALQUENILO C3-C8, ALQUINILO C3-C8, CICLOALQUILO C3-C8, FENILO, FENIL(ALQUILO)C1-C4. FENILALQUENILO C3-C4, ENTRE OTROS; R2 ES H, ALQUILO C1-C4, FENILO, CICLOALQUILO C3-C6, HETEROCICLO C3-C6; RA ES H, ALQUILO C1-C6, ALQUENILO C3-C8, ALQUINILO C3-C8, CICLOALQUILO C3-C8, FENILO, (CICLOALQUILO C3-C8)ALQUILO C1-C4, ENTRE OTROS; RB ES H, ALQUILO C1-C8, CICLOALQUILO C3-C8, FENILO; Q ES EL GRUPO a, ENTRE OTROS; R3 ES H, F; R4 ES HALO, NO2, SO2NRo(CH2)2-4NREFE, ENTRE OTROS; T ES ALQUILO C1-C8, CICLOALQUILO C3-C8, ENTRE OTROS; Z ES EL GRUPO iv, ENTRE OTROS; UNO DE R5 Y R6 ES H, METILO Y EL OTRO ES H, ALQUILO C1-C6, ALQUENILO C2-C6, FENILO, ENTRE OTROS; R10 Y R11 SON H, METILO, HALO, NO2. SON COMPUESTOS PREFERIDOS ACIDO 7-FLUORO-6-(4-YODO-2-METIL-FENILAMINO)-1H-BENZOIMIDAZOL-5-CARBOXILICO, ACIDO 7-FLUORO-6-(4-YODO-2-METIL-FENILAMINO)-1H-BENZOIMIDAZOL-5-CARBOXILICO, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DEL DOLOR CRONICO, NEUROPATICOIT REFERS TO THE USE OF A COMPOSITION INCLUDING A MEK KINASE INHIBITOR OF FORMULA I, WHERE: W IS OR1, NR2OR1, NRARB, NR2NRARB, O (CH2) 2-4NRARB, NR2 (CH2) 2-4, R1 IS H, C1-C8 ALKYL, C3-C8 ALKENYL, C3-C8 ALKYL, C3-C8 CYCLOALKYL, PHENYL, C1-C4 PHENYL (ALKYL). PHENYLALKENYL C3-C4, AMONG OTHERS; R2 IS H, C1-C4 ALKYL, PHENYL, C3-C6 CYCLOALKYL, C3-C6 HETEROCYCLE; RA IS H, C1-C6 ALKYL, C3-C8 ALKENYL, C3-C8 ALKYNYL, C3-C8 CYCLOALKYL, PHENYL, (C3-C8 CYCLOALKYL) C1-C4 ALKYL, AMONG OTHERS; RB IS H, C1-C8 ALKYL, C3-C8 CYCLOALKYL, PHENYL; Q IS THE GROUP a, AMONG OTHERS; R3 IS H, F; R4 IS HALO, NO2, SO2NRo (CH2) 2-4NREFE, AMONG OTHERS; T IS C1-C8 ALKYL, C3-C8 CYCLOALKYL, AMONG OTHERS; Z IS GROUP iv, AMONG OTHERS; ONE OF R5 AND R6 IS H, METHYL AND THE OTHER IS H, C1-C6 ALKYL, C2-C6 ALKENYL, PHENYL, AMONG OTHERS; R10 AND R11 ARE H, METHYL, HALO, NO2. PREFERRED COMPOUNDS ARE 7-FLUORO-6- (4-IODO-2-METHYL-PHENYLAMINE) -1H-BENZOIMIDAZOL-5-CARBOXYL ACID, 7-FLUORO-6- (4-IODO-2-METHYL-PHENYLAMINE) -1H -BENZOIMIDAZOLE-5-CARBOXYLICO, AMONG OTHERS. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF CHRONIC, NEUROPATHIC PAIN

PE2000000704A 1999-07-16 2000-07-14 USE OF A COMPOSITION OF BENZOHETERO CYCLES AS MEK INHIBITORS TO TREAT CHRONIC PAIN PE20010546A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14441899P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
PE20010546A1 true PE20010546A1 (en) 2001-06-04

Family

ID=22508500

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000704A PE20010546A1 (en) 1999-07-16 2000-07-14 USE OF A COMPOSITION OF BENZOHETERO CYCLES AS MEK INHIBITORS TO TREAT CHRONIC PAIN

Country Status (13)

Country Link
EP (1) EP1202731A2 (en)
JP (1) JP2003504398A (en)
KR (1) KR20020015376A (en)
CN (1) CN1358094A (en)
AU (1) AU6068600A (en)
CA (1) CA2377092A1 (en)
CO (1) CO5190704A1 (en)
HU (1) HUP0202319A3 (en)
IL (1) IL147150A0 (en)
PE (1) PE20010546A1 (en)
PL (1) PL352835A1 (en)
WO (1) WO2001005390A2 (en)
ZA (1) ZA200109906B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
AU2002310441A1 (en) * 2001-06-14 2003-01-02 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
WO2003077914A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1482944A4 (en) * 2002-03-13 2006-04-19 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
ES2331246T3 (en) 2003-07-24 2009-12-28 Warner-Lambert Company Llc DERIVATIVES OF BENZAMIDAZOL AS INHIBITORS OF THE MEK.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP5042626B2 (en) 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド Benzimidazole derivatives: production and pharmaceutical applications
AU2004293018B2 (en) 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
CA2546754A1 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
ES2378760T3 (en) 2005-05-18 2012-04-17 Array Biopharma, Inc. MEK heterocyclic inhibitors and methods of use thereof
WO2007002157A2 (en) 2005-06-23 2007-01-04 Array Biopharma Inc. Process for preparing benzimidazole compounds
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
ATE532789T1 (en) 2006-07-06 2011-11-15 Array Biopharma Inc DIHYDROTHIENOPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150041164A (en) 2006-07-06 2015-04-15 어레이 바이오파마 인크. Cyclopenta〔d〕pyrimidines as akt protein kinase inhibitors
CN105106199A (en) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 Methods of using MEK inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
KR101624361B1 (en) 2007-07-05 2016-05-25 어레이 바이오파마 인크. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR067413A1 (en) 2007-07-05 2009-10-07 Genentech Inc HETEROCICLICAL COMPOUNDS CONTAINING CYCLOPENTA [D] PYRIMIDINE INHIBITORS OF AKT PROTEINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD OF PREPARATION AND USE OF THE SAME FOR THE TREATMENT OF HYPER-TROLIFERATIVE TIPERIFERATIVE AS-ISSUES
JP5421925B2 (en) 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド 5-Anilinoimidazopyridine and method of use
US8293763B2 (en) 2007-12-19 2012-10-23 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
EP2220092B1 (en) 2007-12-21 2012-06-06 Genentech, Inc. Azaindolizines and methods of use
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
BRPI0910200A2 (en) 2008-07-01 2015-09-29 Genentech Inc compound, pharmaceutical composition, method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal and method of treating an inflammatory disease in a mammal
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
CN102574782B (en) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 Substituted halophenoxybenzamide derivatives
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
CN103282351A (en) 2010-10-29 2013-09-04 拜耳知识产权有限责任公司 Substituted phenoxypyridines
EP2694072B2 (en) 2011-04-01 2024-08-07 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
CN103841976A (en) 2011-04-01 2014-06-04 基因泰克公司 Combinations of AKT and MEK inhibitor compounds and methods of use thereof
ES2396764B1 (en) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid P38 INHIBITING DRUGS AND APPLICATIONS.
JP5977837B2 (en) 2011-12-21 2016-08-24 ノヴィラ・セラピューティクス・インコーポレイテッド Hepatitis B antiviral agent
CN103204822B (en) 2012-01-17 2014-12-03 上海科州药物研发有限公司 Benzoxazole compounds as protein kinase inhibitors, and preparation method and application thereof
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
NZ706723A (en) 2012-10-12 2018-07-27 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
FI3702351T3 (en) * 2012-10-19 2024-01-24 Array Biopharma Inc Formulation comprising a mek inhibitor
MX366123B (en) 2013-02-28 2019-06-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b.
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EA027068B1 (en) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
PL3024819T3 (en) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3060547B1 (en) 2013-10-23 2017-10-11 Janssen Sciences Ireland UC Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN104774188B (en) * 2014-01-15 2019-10-11 江苏恒瑞医药股份有限公司 Benzoheterocycles or benzoheteroaromatic derivatives, their preparation method and their application in medicine
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
CN110483484A (en) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN107847762A (en) 2015-03-19 2018-03-27 诺维拉治疗公司 Azacyclooctane and azacyclononane derivatives and methods of treating hepatitis B infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1259410A1 (en) 2015-09-29 2019-11-29 诺维拉治疗公司 Crystalline forms of a hepatitis b antiviral agent
CN109640980A (en) 2016-04-15 2019-04-16 诺维拉治疗公司 Combination and method comprising shell assembly inhibitor
AR108257A1 (en) 2016-05-02 2018-08-01 Mei Pharma Inc POLYMORPHIC FORMS OF 3- [2-BUTIL-1- (2-DIETILAMINO-ETIL) -1H-BENCIMIDAZOL-5-IL] -N-HYDROXY-ACRYLAMIDE AND USES OF THE SAME
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
JP2022521081A (en) 2019-02-22 2022-04-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Amide derivatives useful in the treatment of HBV infections or HBV-induced diseases
MA55879A (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS
CN110981819B (en) * 2019-12-24 2022-07-01 广西师范大学 Quinoxaline signal channel inhibitor and preparation method and application thereof
CN114788867A (en) * 2022-04-24 2022-07-26 天津医科大学总医院 Application of Map2k1 as a therapeutic target for post-chemotherapy neuralgia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
HK1041697A1 (en) * 1999-01-13 2002-07-19 沃尼尔‧朗伯公司 Benzoheterocycles and their use as mek inhibitors

Also Published As

Publication number Publication date
KR20020015376A (en) 2002-02-27
CA2377092A1 (en) 2001-01-25
EP1202731A2 (en) 2002-05-08
HUP0202319A2 (en) 2002-10-28
PL352835A1 (en) 2003-09-08
HUP0202319A3 (en) 2004-12-28
IL147150A0 (en) 2002-08-14
CN1358094A (en) 2002-07-10
AU6068600A (en) 2001-02-05
JP2003504398A (en) 2003-02-04
WO2001005390A2 (en) 2001-01-25
WO2001005390A3 (en) 2001-05-17
CO5190704A1 (en) 2002-08-29
ZA200109906B (en) 2003-05-28

Similar Documents

Publication Publication Date Title
PE20010546A1 (en) USE OF A COMPOSITION OF BENZOHETERO CYCLES AS MEK INHIBITORS TO TREAT CHRONIC PAIN
PE20230820A1 (en) BIARYL DERIVATIVES AS INHIBITORS OF YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION
PE20020855A1 (en) PIPERAZINE DERIVATIVES AZAINDOLOXOACETICO SUBSTITUTED WITH ANTIVIRAL ACTIVITY
PE133999A1 (en) HYDROXAMIC ACID DERIVATIVES AS MATRIX METALOPROTEASE INHIBITORS (MMP)
PE20020585A1 (en) METALOPROTEINASE INHIBITORS OF THE TYPE PYRIMIDIN-2,4,6-TRIONA
PE20070189A1 (en) AMINO-5-HETEROARYL COMPOUND (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR ß-SECRETASE MODULATION
PE20020548A1 (en) IMIDAZOLE COMPOUNDS CONDENSED WITH ARYL OR HETEROARIL AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS
PE20060363A1 (en) DERIVATIVES OF TETRAAZABENZO [e] AZULENO AND ITS ANALOGS
PE20020483A1 (en) SELECTIVE CYCLIC PEPTIDES AS AGONISTS OF MELANOCORTIN 4 RECEPTORS
PE20020131A1 (en) DERIVATIVES OF PIRAZOLE
RU2011106374A (en) CYCLIC INHIBITORS 11BETA-HYDROXYSTEROID-DEHYDROGENASE 1
PE20141681A1 (en) BTK INHIBITORS
PE20030440A1 (en) PHENYLSULPHONAMIDES AS ANTAGONISTS OF CCR3
PE20120355A1 (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF THE ENZYME 11ßHSD1
PE20020509A1 (en) AZA AND POLIAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS INHIBITORS OF HIV INTEGRASE
PE20091573A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AS INHIBITORS OF DNA GIRASE AND / OR TOPOISOMERASE
PE20130385A1 (en) DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS
PE68699A1 (en) PIRAZOLOPIRIMIDONAS FOR SEXUAL DYSFUNCTION
FI865037A7 (en) MICROBICIDAL COMPOSITION.
PE20191757A1 (en) HELPFUL HETEROCYCLIC COMPOUNDS AS DOUBLE ATX / AC INHIBITORS
PE20011068A1 (en) 1,3-PYRROLIDINES DISUSTITUTED
PE20011089A1 (en) OXAZOLIDINONE THIOAMIDES WITH PIPERAZIN-AMIDE SUBSTITUTES
PE20011008A1 (en) PYRIMIDINE DERIVATIVES AS CYCLOOXYGENASE 2 INHIBITORS
NO883487D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE HETEROCYCLIC COMPOUNDS.
PE20230679A1 (en) HETEROCYCLIC PAD4 INHIBITORS

Legal Events

Date Code Title Description
FD Application declared void or lapsed